Rhythm Pharmaceuticals’ obesity drug cuts BMI by up to 18.8% in two-year trial
Long-term trial findings presented at ObesityWeek 2026 showed sustained reductions in body mass index among patients receiving the therapy.
Published
Original News Source
The Hindu BusinessLine
Source Website
www.thehindubusinessline.com ↗
Content & Media Rights
The Hindu BusinessLine
Editorial Publisher
360 NEWS (Independent Media)
360 News
Long-term trial findings presented at ObesityWeek 2026 showed sustained reductions in body mass index among patients receiving the therapy.
Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].

